Nama's AI scorecard currently rates Butterfly Network Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does BFLY report earnings?

Butterfly Network's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.02.

What is the BFLY price target?

The median analyst price target from 6 analysts is $10.50, with a range of $10.00 – $15.00.

Is BFLY Shariah compliant?

Nama's AAOIFI-style screen reads Butterfly Network as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Butterfly Network (BFLY)

Healthcare · Medical Devices · NYSE

Butterfly Network (BFLY) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.70B and a free-cash-flow yield of -0.9%. Over the most recent reported fiscal year, revenue grew 19.0%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +267.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-39.3%

How far the last close sits under the highest price of the past five years.

Market cap	$1.70B
Trailing P/E	—
Price / book	9.2
Price / sales	13.8
FCF yield	-0.9%
Dividend yield	—
Gross margin	70.3%
Operating margin	-46.9%
Net margin	-43.6%
Revenue growth (YoY)	+19.0%
Revenue growth (3-yr annual)	+10.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.0
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

BFLY earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.02). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$0.01	-$0.04	+75.0%	$32.60M
Q2 2026	Jul 30, 2026	-$0.01	-$0.03	+66.7%	$32.61M
Q1 2026	Apr 30, 2026	-$0.03	-$0.05	+40.0%	$26.53M
Q4 2025	Feb 26, 2026	-$0.02	-$0.04	+50.0%	$31.51M

BFLY analyst price target

Median target $10.50 from 6 analysts, ranging $10.00 – $15.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live BFLY data on Nama Insights →

BFLY FAQ

Is BFLY a buy?: Nama's AI scorecard currently rates Butterfly Network Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BFLY report earnings?: Butterfly Network's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.02.
What is the BFLY price target?: The median analyst price target from 6 analysts is $10.50, with a range of $10.00 – $15.00.
Is BFLY Shariah compliant?: Nama's AAOIFI-style screen reads Butterfly Network as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.